{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:50:11Z","timestamp":1791575411344,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Research, Development and Innovation Office of Hungary","award":["NVKP-16-1-2016-0017 National Heart Program"],"award-info":[{"award-number":["NVKP-16-1-2016-0017 National Heart Program"]}]},{"DOI":"10.13039\/501100015498","name":"Ministry for Innovation and Technology","doi-asserted-by":"crossref","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}],"id":[{"id":"10.13039\/501100015498","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Development and Innovation Office of the Ministry of Innovation and Technology","award":["TKP\/ITM\/NKFIH"],"award-info":[{"award-number":["TKP\/ITM\/NKFIH"]}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["\u00daNKP-20-4-I-SE-7"],"award-info":[{"award-number":["\u00daNKP-20-4-I-SE-7"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["\u00daNKP-21-4-II-SE-18"],"award-info":[{"award-number":["\u00daNKP-21-4-II-SE-18"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005881","name":"Emberi Eroforr\u00e1sok Miniszt\u00e9riuma","doi-asserted-by":"crossref","award":["EFOP-3.6.3-VEKOP-16-2017-00009"],"award-info":[{"award-number":["EFOP-3.6.3-VEKOP-16-2017-00009"]}],"id":[{"id":"10.13039\/501100005881","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["RRF-2.3.1-21-2022-00003"],"award-info":[{"award-number":["RRF-2.3.1-21-2022-00003"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002332","name":"Semmelweis University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002332","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s40264-022-01225-9","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T03:26:45Z","timestamp":1665026805000},"page":"1423-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Network Analysis for Signal Detection in Spontaneous Adverse Event Reporting Database: Application of Network Weighting Normalization to Characterize Cardiovascular Drug Safety"],"prefix":"10.1007","volume":"45","author":[{"given":"M\u00e1ty\u00e1s","family":"P\u00e9terv\u00e1ri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Benczik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliv\u00e9r M.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Petrovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"\u00c1gg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Ferdinandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"1225_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008;42:409\u201319.","journal-title":"Drug Inf J"},{"key":"1225_CR2","unstructured":"FDA Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-adverse-event-reporting-system-faers. Accessed 6 Jun 2022."},{"key":"1225_CR3","unstructured":"EudraVigilance | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/pharmacovigilance\/eudravigilance. Accessed 6 Jun 2022."},{"key":"1225_CR4","unstructured":"European Medicines Agency. 2020 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/report\/2020-annual-report-eudravigilance-european-parliament-council-commission_en.pdf"},{"key":"1225_CR5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1225_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K, Thakrar B, Quarcoo N, Seabroke S, et al. Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf. 2015;38:577\u201387.","journal-title":"Drug Saf"},{"key":"1225_CR7","unstructured":"Screening for adverse reactions in EudraVigilance. EMA\/849944\/2016. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf. Accessed 6 Jun 2022."},{"key":"1225_CR8","unstructured":"IME list inclusion-exclusion criteria | Enhanced Reader. moz-extension:\/\/5e9ac340-9326-460e-810f-793f4312e4d6\/enhanced-reader.html?openApp&pdf=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fdocuments%2Fother%2Feudravigilance-inclusion%2Fexclusion-criteria-important-medical-events-list_en.pdf. Accessed 17 Dec 2018."},{"key":"1225_CR9","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","volume":"41","author":"R Postigo","year":"2018","unstructured":"Postigo R, Brosch S, Slattery J, van Haren A, Dogn\u00e9 JM, Kurz X, et al. EudraVigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf. 2018;41:665\u201375.","journal-title":"Drug Saf"},{"key":"1225_CR10","unstructured":"European Medicines Agency. European Medicines Agency policy on access to EudraVigilance data for medicinal products for human use. EMA\/759287\/2009 Revis. 4. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/other\/european-medicines-agency-policy-access-eudravigilance-data-medicinal-products-human-use-revision-4_en.pdf."},{"key":"1225_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1002\/pds.4247","volume":"26","author":"O Caster","year":"2017","unstructured":"Caster O, Sandberg L, Bergvall T, Watson S, Nor\u00e9n GN. vigiRank for statistical signal detection in pharmacovigilance: first results from prospective real-world use. Pharmacoepidemiol Drug Saf. 2017;26:1006\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1225_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jbi.2015.06.011","volume":"56","author":"JM Reps","year":"2015","unstructured":"Reps JM, Garibaldi JM, Aickelin U, Gibson JE, Hubbard RB. A supervised adverse drug reaction signalling framework imitating Bradford Hill\u2019s causality considerations. J Biomed Inform. 2015;56:356\u201368.","journal-title":"J Biomed Inform"},{"key":"1225_CR13","doi-asserted-by":"publisher","first-page":"48812","DOI":"10.1109\/ACCESS.2020.2979452","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Ji X, Hua L. Improving the prediction of adverse drug events using feature fusion-based predictive network models. IEEE Access. 2020;8:48812\u201321.","journal-title":"IEEE Access."},{"key":"1225_CR14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1541-0420.2009.01262.x","volume":"66","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Dalmasso C, Haramburu F, Thiessard F, Bro\u00ebt P, Tubert-Bitter P. False discovery rate estimation for frequentist pharmacovigilance signal detection methods. Biometrics. 2010;66:301\u20139.","journal-title":"Biometrics"},{"key":"1225_CR15","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/clpt.2010.111","volume":"88","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Thiessard F, Miremont-Salam\u00e9 G, B\u00e9gaud B, Tubert-Bitter P. Pharmacovigilance data mining with methods based on false discovery rates: a comparative simulation study. Clin Pharmacol Ther. 2010;88:492\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1225_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-06001-w","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021. https:\/\/doi.org\/10.1007\/s10549-020-06001-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1225_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/pds.3454","volume":"23","author":"P Avillach","year":"2014","unstructured":"Avillach P, Salvo F, Thiessard F, Miremont-Salam\u00e9 G, Fourrier-Reglat A, Haramburu F, et al. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. Pharmacoepidemiol Drug Saf. 2014;23:186\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1225_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3233\/978-1-60750-806-9-564","volume-title":"Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. Studies in Health Technologies and Informatics","author":"T Botsis","year":"2011","unstructured":"Botsis T, Ball R. Network analysis of possible anaphylaxis cases reported to the US vaccine adverse event reporting system after H1N1 influenza vaccine. Studies in Health Technologies and Informatics. New York: IOS Press; 2011. p. 564\u20138. https:\/\/doi.org\/10.3233\/978-1-60750-806-9-564."},{"key":"1225_CR19","doi-asserted-by":"publisher","first-page":"206","DOI":"10.4338\/ACI-2013-11-RA-0097","volume":"5","author":"J Scott","year":"2014","unstructured":"Scott J, Botsis T, Ball R. Simulating adverse event spontaneous reporting systems as preferential attachment networks: application to the vaccine adverse event reporting system. Appl Clin Inform. 2014;5:206\u201318.","journal-title":"Appl Clin Inform"},{"key":"1225_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40264-014-0195-2","volume":"37","author":"A Nazir","year":"2014","unstructured":"Nazir A, Ichinomiya T, Miyamura N, Sekiya Y, Kinosada Y. Identification of suicide-related events through network analysis of adverse event reports. Drug Saf. 2014;37:609\u201316.","journal-title":"Drug Saf"},{"key":"1225_CR21","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s00520-018-4106-4","volume":"26","author":"MG Kim","year":"2018","unstructured":"Kim MG, Jeong CR, Kim HJ, Kim JH, Song YK, Kim KI, et al. Network analysis of drug-related problems in hospitalized patients with hematologic malignancies. Support Care Cancer. 2018;26:2737\u201342.","journal-title":"Support Care Cancer"},{"key":"1225_CR22","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/jcm10194486","volume":"10","author":"A Martinez-De la Torre","year":"2021","unstructured":"Martinez-De la Torre A, van Weenen E, Kraus M, Weiler S, Feuerriegel S, Burden AM. A network analysis of drug combinations associated with acute generalized exanthematous pustulosis (AGEP). J Clin Med. 2021;10:4486.","journal-title":"J Clin Med"},{"key":"1225_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.jbi.2016.07.023","volume":"64","author":"T Botsis","year":"2016","unstructured":"Botsis T, Jankosky C, Arya D, Kreimeyer K, Foster M, Pandey A, et al. Decision support environment for medical product safety surveillance. J Biomed Inform. 2016;64:354\u201362.","journal-title":"J Biomed Inform"},{"key":"1225_CR24","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.3389\/fphar.2021.740707\/full","volume":"12","author":"M Fusaroli","year":"2021","unstructured":"Fusaroli M, Raschi E, Gatti M, De Ponti F, Poluzzi E. Development of a network-based signal detection tool: the COVID-19 adversome in the FDA adverse event reporting system. Front Pharmacol. 2021;12:3542. https:\/\/doi.org\/10.3389\/fphar.2021.740707\/full.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1225_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/27714","volume":"23","author":"A Lavertu","year":"2021","unstructured":"Lavertu A, Hamamsy T, Altman RB. Quantifying the severity of adverse drug reactions using social media: network analysis. J Med Internet Res. 2021;23(10): e27714.","journal-title":"J Med Internet Res"},{"key":"1225_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3109\/10408444.2016.1149452","volume":"46","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol. 2016;46:477\u201389.","journal-title":"Crit Rev Toxicol"},{"key":"1225_CR27","unstructured":"PRAC recommendations on safety signals | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/pharmacovigilance\/signal-management\/prac-recommendations-safety-signals. Accessed 6 Jun 2022."},{"issue":"2","key":"1225_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20(2):109\u201317.","journal-title":"Drug Saf"},{"key":"1225_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3233\/978-1-61499-432-9-1178","volume-title":"Novel algorithms for improved pattern recognition using the US FDA adverse event network analyzer. Studies in health technologies and informatics","author":"T Botsis","year":"2014","unstructured":"Botsis T, Scott J, Goud R, Toman P, Sutherland A, Ball R. Novel algorithms for improved pattern recognition using the US FDA adverse event network analyzer. Studies in health technologies and informatics. New York: IOS Press; 2014. p. 1178\u201382. https:\/\/doi.org\/10.3233\/978-1-61499-432-9-1178."},{"key":"1225_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1093\/jamia\/ocy097","volume":"25","author":"B Davazdahemami","year":"2018","unstructured":"Davazdahemami B, Delen D. A chronological pharmacovigilance network analytics approach for predicting adverse drug events. J Am Med Informatics Assoc. 2018;25:1311\u201321.","journal-title":"J Am Med Informatics Assoc."},{"key":"1225_CR31","doi-asserted-by":"crossref","unstructured":"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074\u201382.","DOI":"10.1093\/nar\/gkx1037"},{"key":"1225_CR32","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"1225_CR33","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1093\/bioinformatics\/btz257","volume":"35","author":"B \u00c1gg","year":"2019","unstructured":"\u00c1gg B, Cs\u00e1sz\u00e1r A, Szalay-Bek\u0151 M, Veres DV, Mizsei R, Ferdinandy P, et al. The EntOptLayout Cytoscape plug-in for the efficient visualization of major protein complexes in protein\u2013protein interaction and signalling networks. Valencia A, editor. Bioinformatics. 2019;35:4490\u20132.","journal-title":"Bioinformatics"},{"key":"1225_CR34","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44:D1075\u20139.","journal-title":"Nucleic Acids Res"},{"key":"1225_CR35","unstructured":"PROTECT Home. http:\/\/www.imi-protect.eu\/adverseDrugReactions.shtml. Accessed 13 Jan 2018."},{"key":"1225_CR36","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345. https:\/\/doi.org\/10.2307\/2531595.","journal-title":"Biometrics"},{"key":"1225_CR37","unstructured":"R: The R Project for Statistical Computing. https:\/\/www.r-project.org\/. Accessed 6 Jun 2022."},{"key":"1225_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 2011;12:77. https:\/\/doi.org\/10.1186\/1471-2105-12-77.","journal-title":"BMC Bioinform"},{"key":"1225_CR39","unstructured":"CRAN\u2014Package rjson. https:\/\/cran.r-project.org\/web\/packages\/rjson\/index.html. Accessed 6 Jun 2022."},{"key":"1225_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13326-015-0032-2","volume":"6","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Wu P, Luo Y, Tao C. Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS. J Biomed Semantics. 2015;6:33.","journal-title":"J Biomed Semantics."},{"key":"1225_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13040-014-0036-y","volume":"7","author":"C Tao","year":"2014","unstructured":"Tao C, Wu P, Luo Y, Zhang Y. Linked vaccine adverse event data from VAERS for biomedical data analysis and longitudinal studies. BioData Min. 2014;7:36.","journal-title":"BioData Min."},{"key":"1225_CR42","unstructured":"Data on medicines (ISO IDMP standards): Overview | European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/data-medicines-iso-idmp-standards-overview. Accessed 6 Jun 2022."},{"key":"1225_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/pds.4970","volume":"29","author":"L Dijkstra","year":"2020","unstructured":"Dijkstra L, Garling M, Foraita R, Pigeot I. Adverse drug reaction or innocent bystander? A systematic comparison of statistical discovery methods for spontaneous reporting systems. Pharmacoepidemiol Drug Saf. 2020;29:396\u2013403.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1225_CR44","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3758\/s13428-017-0862-1","volume":"50","author":"S Epskamp","year":"2018","unstructured":"Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy: a tutorial paper. Behav Res Methods. 2018;50:195\u2013212.","journal-title":"Behav Res Methods"},{"key":"1225_CR45","unstructured":"European Medicines Agency. Electronic product information for human medicines in the EU: key principles A joint EMA-HMA-EC collaboration. https:\/\/www.ema.europa.eu\/en\/electronic-product-information-human-medicines-european-union-key-principles. Accessed 6 Jun 2022."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01225-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-022-01225-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-022-01225-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T15:57:25Z","timestamp":1665676645000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-022-01225-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s40264-022-01225-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"assertion":[{"value":"7 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Semmelweis University. This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program). The Ministry for Innovation and Technology in Hungary provided funding to this study under Thematic Excellence Programme (2020-4.1.1.-TKP2020), 2020-1.1.5-GYORS\u00cdT\u00d3S\u00c1V call programme (2020-1.1.5-GYORS\u00cdT\u00d3S\u00c1V-2021-00011), TKP2021-EGA funding scheme (TKP2021-EGA-23), Research Excellence Programme (TKP\/ITM\/NKFIH). This study was also supported by\u00a0Project no. RRF-2.3.1-21-2022-00003 implemented with the support provided by the EU. B\u00c1 was supported by the New National Excellence Program of the Ministry for Innovation and Technology from the National Research, Development and Innovation Fund source (\u00daNKP-20-4-I-SE-7, \u00daNKP-21-4-II-SE-18), and MP was supported by EFOP-3.6.3-VEKOP-16-2017-00009 \u201cSemmelweis 250+ Kiv\u00e1l\u00f3s\u00e1gi PhD \u00d6szt\u00f6nd\u00edj\u201d grant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"PF is the founder and CEO of, and B\u00c1 is employed by, Pharmahungary Group, a group of research and development (R&D) companies () and the provider of Vigilace\u2122. MP is the founder and CEO of Sanovigado Kft, a pharmaceutical consultancy and R&D company. BB, OB, and BP declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"Ethics approval was obtained from the Semmelweis University Regional and Institutional Committee of Science and Research Ethics (SE RKEB 82\/2018)","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This study was based on administrative claims data and therefore did not require patient consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Unpublished data related to this study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The code is the intellectual property of Pharmahungary Group and Semmelweis University.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MP: Software coding and architecture design; study design; data curation, analysis, and interpretation; drafting of the manuscript. BB: Statistical analysis, data interpretation. OB, BP: Software coding. B\u00c1: Software architecture, study design, data interpretation, critical revision of the manuscript. PF: Funding acquisition, study design, critical revision of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}